Literature DB >> 6611230

Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis.

P Emery, G S Panayi, A M Nouri.   

Abstract

The depressed cell-mediated immunity in rheumatoid arthritis was investigated in vivo by cutaneous hypersensitivity responses to seven antigens including tuberculin PPD, and in vitro by lymphocyte transformation to the latter antigen. In vivo 40% of rheumatoid patients were anergic compared to 2% of controls (P less than 0.001) with an associated reduction in sum score (5.9 +/- 6.5 vs 15.3 +/- 8.7, P less than 0.001). In vitro lymphocyte proliferation to PPD was also significantly depressed (P less than 0.001) and could not be reversed by indomethacin. A significant correlation between the in vivo sum scored (induration in mm) and in vitro thymidine incorporation (d/min) (r = 0.59, P less than 0.001) was found. In an attempt to overcome the depressed in vitro response the addition of a crude supernatant from a mixed lymphocyte reaction was found to return the PPD stimulated lymphocyte proliferation to the normal range. This effect was mimicked by purified IL-2 but not purified IL-1. The implications of this finding are are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611230      PMCID: PMC1536082     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Studies on T lymphocyte activation. I. Requirements for the mitogen-dependent production of T cell growth factors.

Authors:  J Andersson; K O Grönvik; E L Larsson; A Coutinho
Journal:  Eur J Immunol       Date:  1979-08       Impact factor: 5.532

3.  Cellular immunity in rheumatic diseases. I. Rheumatoid arthritis.

Authors:  J Waxman; M D Lockshin; J J Schnapp; I N Doneson
Journal:  Arthritis Rheum       Date:  1973 Jul-Aug

4.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

5.  Role of prostaglandin in the depressed cell-mediated immune response in rheumatoid arthritis.

Authors:  S I Wolinsky; J S Goodwin; R P Messner; R C Williams
Journal:  Clin Immunol Immunopathol       Date:  1980-09

Review 6.  Immunological phenomena in leprosy and related diseases.

Authors:  J L Turk; A D Bryceson
Journal:  Adv Immunol       Date:  1971       Impact factor: 3.543

7.  Altered lymphocyte reactivity in rheumatoid arthritis.

Authors:  H A Silverman; J S Johnson; J H Vaughan; J C McGlamory
Journal:  Arthritis Rheum       Date:  1976 May-Jun

8.  Suppressor cell function in sarcoidosis.

Authors:  J S Goodwin; R DeHoratius; H Israel; G T Peake; R P Messner
Journal:  Ann Intern Med       Date:  1979-02       Impact factor: 25.391

9.  Cell-mediated immunity in rheumatic diseases. II. Mitogen responses in RA, SLE, and other illnesses: correlation with T- and B-lymphocyte populations.

Authors:  M D Lockshin; A C Eisenhauer; R Kohn; M Weksler; S Block; S B Mushlin
Journal:  Arthritis Rheum       Date:  1975 May-Jun

10.  Biochemical and biological characterization of lymphocyte regulatory molecules. I. Purification of a class of murine lymphokines.

Authors:  J Watson; S Gillis; J Marbrook; D Mochizuki; K A Smith
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  39 in total

1.  Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2.

Authors:  Y Zaloom; L P Walsh; P McCulloch; G Gallagher
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

Review 2.  Co-stimulatory blockade as therapy for rheumatoid arthritis.

Authors:  Sarah L Mackie; Edward M Vital; Frederique Ponchel; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

3.  Attenuated response to purified protein derivative in patients with rheumatoid arthritis.

Authors:  S Nizam; P Emery
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

4.  QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis?

Authors:  Petros Efthimiou; Sunita Sood
Journal:  Ann Rheum Dis       Date:  2006-11-24       Impact factor: 19.103

5.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

6.  Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.

Authors:  L Berg; J Lampa; S Rogberg; R van Vollenhoven ; L Klareskog
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

7.  Interleukin 2 inhibitor in synovial fluid.

Authors:  P Emery; K C Gentry; A Kelso; I R Mackay
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

8.  Defective cell mediated immunity in sarcoidosis: effect of interleukin-2.

Authors:  D J Lyons; L Gao; E B Mitchell; D N Mitchell
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

9.  Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis.

Authors:  C Plater-Zyberk; K A Rockett; R N Maini
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

10.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.